Trial Profile
Phase II Study of Neo-Adjuvant Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Malignant Pleural Mesothelioma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 May 2017
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 17 Sep 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 14 May 2009 New trial record